Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;82(2):767-776.
doi: 10.1007/s12013-024-01226-8. Epub 2024 Feb 8.

Berberine ameliorates the progression of primary sclerosing cholangitis by activating farnesoid X receptor

Hassan Hameed  1 , Nida Irshad  1 , Muhammad Abrar Yousaf  2 , Sidra Mumtaz  1 , Imran Sohail  3
Affiliations

Berberine ameliorates the progression of primary sclerosing cholangitis by activating farnesoid X receptor

Hassan Hameed et al. Cell Biochem Biophys. 2024 Jun.

Abstract

Primary sclerosing cholangitis (PSC) is a rare cholestatic disease characterized by biliary infiltration, hepatic fibrosis and bile duct destruction. To date, treatment options for PSC are very limited. Therefore, the current study is aimed to investigate the therapeutic potential of berberine (BBR) against PSC. The disease was induced by feeding the mice with 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-collidine (DDC) for four weeks. The serum biochemistry and liver histology were analyzed. Furthermore, the expression of farnesoid X receptor (FXR) was also evaluated by real-time PCR. The results indicated that berberine prevents the progression of PSC by modulating the expression of FXR which ultimately regulates other genes (including Cyp7A1 and BSEP) thus maintaining bile acids homeostasis. Furthermore, the docking analysis showed that berberine interacts with the binding pocket of FXR to activate the protein thus acting as an FXR agonist. In conclusion, data indicate that berberine protects the liver from PSC-related injury. This effect might be due to the modulation of FXR activity.

Keywords: BSEP; Berberine; Cyp7A1; DDC; FXR; Primary Sclerosing Cholangitis.

PubMed Disclaimer

References

    1. Fickert, P., Pollheimer, M. J., Beuers, U., Lackner, C., Hirschfield, G., Housset, C., Keitel, V., Schramm, C., Marschall, H. U., Karlsen, T. H., Melum, E., Kaser, A., Eksteen, B., Strazzabosco, M., Manns, M., & Trauner, M. (2014). Characterization of animal models for primary sclerosing cholangitis (PSC). Journal of Hepatology, 60, 1290–1303. - PubMed - PMC - DOI
    1. Eaton, J. E., Talwalkar, J. A., Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2013). Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology, 145, 521–536. - PubMed - DOI
    1. Lindor, K. D., Kowdley, K. V., Luketic, V. A., Harrison, M. E., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., Mooney, J., Sargeant, C., Braaten, J., Bernard, T., King, D., Miceli, E., Schmoll, J., Hoskin, T., Thapa, P., & Enders, F. (2009). High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology, 50, 808–814. - PubMed - DOI
    1. Giljaca, V., Poropat, G., Stimac, D., & Gluud, C. (2010). Glucocorticosteroids for primary sclerosing cholangitis. The Cochrane Database of Systematic Reviews, 2010, Cd004036. - PubMed - PMC
    1. Mousavere, I., Kalampokis, G., Fousekis, F., Karayiannis, P., Baltayiannis, G., & Christodoulou, D. (2023). An overview of recent treatment options for primary sclerosing cholangitis. Annals of Gastroenterology, 36, 589–598. - PubMed - PMC

MeSH terms

LinkOut - more resources